Recently, the extranet disclosed significant regulatory amendments within the medical device and pharmaceutical domains in both the United States and the United Kingdom, meriting attention throughout 2024. In the United States, noteworthy is the inclusion of LDT (laboratory-developed testing) within the ambit of FDA oversight, alongside the Biden administration’s proposition of invoking March-in rights. In the United Kingdom, attention is drawn to the VPAG (Voluntary Scheme for the Pricing, Access, and Growth of Branded Medicines), positioned to supplant the CE marking, UKCA certification, and the VPAS (Voluntary Scheme for the Pricing and Access to Branded Medicines). The regulation of LDTs typically pertains to test methodologies crafted, authenticated, and utilized exclusively…